Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | WT2725 |
Synonyms | |
Therapy Description |
WT2725 is a oligopeptide vaccine that induces WT1-specific cytotoxic T-lymphocytes, potentially resulting in antitumor activity against WT1-positive tumors (Journal of Clinical Oncology 35, no. 15_suppl (May 20 2017) 2066-2066). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
WT2725 | WT2725 is a oligopeptide vaccine that induces WT1-specific cytotoxic T-lymphocytes, potentially resulting in antitumor activity against WT1-positive tumors (Journal of Clinical Oncology 35, no. 15_suppl (May 20 2017) 2066-2066). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
Unknown unknown | glioblastoma | not applicable | WT2725 | Phase I | Actionable | In a Phase I trial, WT2725 treatment resulted in survival for more than a year in 33% (7/21) of patients with progressive or recurrent glioblastoma, with 3 patients survived over 18 months, 2 survived over 2 years (both in complete radiologic remission) (Journal of Clinical Oncology 35, no. 15_suppl (May 20 2017) 2066-2066; NCT01621542). | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01621542 | Phase I | WT2725 | Clinical Study of WT2725 in Patients With Advanced Malignancies | Completed | USA | 0 |